{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T19:56:58Z","timestamp":1767988618847,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1016\/j.clinthera.2014.12.010","type":"journal-article","created":{"date-parts":[[2015,1,30]],"date-time":"2015-01-30T00:42:17Z","timestamp":1422578537000},"page":"585-596","source":"Crossref","is-referenced-by-count":13,"title":["Efficacy and Tolerability of Intranasal Fentanyl Spray in Cancer Patients With Breakthrough Pain"],"prefix":"10.1016","volume":"37","clinical-trial-number":[{"clinical-trial-number":"nct01429051","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Morten","family":"Thron\u00e6s","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1323-2938","authenticated-orcid":false,"given":"Lars","family":"Popper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3824-744X","authenticated-orcid":false,"given":"Martin","family":"Eeg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1562-1593","authenticated-orcid":false,"given":"Ellen","family":"Jaatun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magnar","family":"Kvitberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stein","family":"Kaasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2014.12.010_bib1","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/annonc\/mdm056","article-title":"Prevalence of pain in patients with cancer: a systematic review of the past 40 years","volume":"18","author":"van den Beuken-van Everdingen","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2014.12.010_bib2","doi-asserted-by":"crossref","first-page":"e58","DOI":"10.1016\/S1470-2045(12)70040-2","article-title":"Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC","volume":"13","author":"Caraceni","year":"2012","journal-title":"Lancet Oncol"},{"issue":"8 Suppl","key":"10.1016\/j.clinthera.2014.12.010_bib3","first-page":"25","article-title":"Breakthrough pain: definition and management","volume":"3","author":"Portenoy","year":"1989","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.clinthera.2014.12.010_bib4","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.jpainsymman.2013.02.015","article-title":"Prevalence of Breakthrough Cancer Pain: A Systematic Review and a Pooled Analysis of Published Literature","volume":"47","author":"Deandrea","year":"2014","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.clinthera.2014.12.010_bib5","first-page":"57","article-title":"Breakthrough Cancer Pain: An Observational Study of 1000 European Oncology Patients","volume":"47","author":"Davies","year":"2014","journal-title":"J Pain Symptom Manage"},{"issue":"6","key":"10.1016\/j.clinthera.2014.12.010_bib6","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0885-3924(98)00094-3","article-title":"Peak plasma concentrations after oral morphine: a systematic review","volume":"16","author":"Collins","year":"1998","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.clinthera.2014.12.010_bib7","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/s11916-011-0191-5","article-title":"Managing breakthrough pain","volume":"15","author":"Mercadante","year":"2011","journal-title":"Curr Pain Headache Rep"},{"key":"10.1016\/j.clinthera.2014.12.010_bib8","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2165\/11630580-000000000-00000","article-title":"A comprehensive review of rapid-onset opioids for breakthrough pain","volume":"26","author":"Smith","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2014.12.010_bib9","doi-asserted-by":"crossref","unstructured":"Zeppetella G, Davies A, Eijgelshoven I, Jansen JP. A Network Meta-Analysis of the Efficacy of Opioid Analgesics for the Management of Breakthrough Cancer Pain Episodes. J Pain Symptom Manage. 47:772\u2013785.e5.","DOI":"10.1016\/j.jpainsymman.2013.05.020"},{"key":"10.1016\/j.clinthera.2014.12.010_bib10","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1034\/j.1399-6576.2002.460702.x","article-title":"Nasal administration of opioids for pain management in adults","volume":"46","author":"Dale","year":"2002","journal-title":"Acta Anaesthesiol Scand"},{"key":"10.1016\/j.clinthera.2014.12.010_bib11","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1007\/BF02527870","article-title":"[Pharmacokinetics of intranasal Fentanyl.]","volume":"7","author":"Striebel","year":"1993","journal-title":"Schmerz"},{"key":"10.1016\/j.clinthera.2014.12.010_bib12","doi-asserted-by":"crossref","first-page":"17","DOI":"10.5055\/jom.2010.0001","article-title":"Pharmacokinetics of intranasal fentanyl spray in patients with cancer and breakthrough pain","volume":"6","author":"Kaasa","year":"2010","journal-title":"J Opioid Manag"},{"key":"10.1016\/j.clinthera.2014.12.010_bib13","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1345\/aph.1L168","article-title":"Pharmacokinetics and pharmacodynamics of intranasal versus intravenous fentanyl in patients with pain after oral surgery","volume":"42","author":"Foster","year":"2008","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2014.12.010_bib14","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.clinthera.2008.03.001","article-title":"Pharmacokinetics efficacy, and tolerability of fentanyl following intranasal versus intravenous administration in adults undergoing third-molar extraction: a randomized, double-blind, double-dummy, two-way, crossover study","volume":"30","author":"Christrup","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2014.12.010_bib15","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1016\/j.clinthera.2009.05.022","volume":"31","author":"Kress","year":"2009","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2014.12.010_bib16","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1185\/03007990903336135","article-title":"A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial","volume":"25","author":"Mercadante","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2014.12.010_bib17","doi-asserted-by":"crossref","first-page":"495","DOI":"10.5414\/CP201867","article-title":"An innovative phase I population pharmacokinetic approach to investigate the pharmacokinetics of an intranasal fentanyl spray in healthy subjects","volume":"51","author":"Plock","year":"2013","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2014.12.010_bib18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0304-3959(00)00339-0","article-title":"Defining the clinically important difference in pain outcome measures","volume":"88","author":"Farrar","year":"2000","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2014.12.010_bib19","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/nm.2249","article-title":"Advances in clinical research methodology for pain clinical trials","volume":"16","author":"Farrar","year":"2010","journal-title":"Nat Med"},{"key":"10.1016\/j.clinthera.2014.12.010_bib20","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.jpainsymman.2010.11.004","article-title":"Consistency of efficacy, patient acceptability, and nasal tolerability of fentanyl pectin nasal spray compared with immediate-release morphine sulfate in breakthrough cancer pain","volume":"41","author":"Davies","year":"2011","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.clinthera.2014.12.010_bib21","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.suponc.2011.07.004","article-title":"Efficacy and safety of fentanyl pectin nasal spray compared with immediate-release morphine sulfate tablets in the treatment of breakthrough cancer pain: a multicenter, randomized, controlled, double-blind, double-dummy multiple-crossover study","volume":"9","author":"Fallon","year":"2011","journal-title":"J Support Oncol"},{"key":"10.1016\/j.clinthera.2014.12.010_bib22","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.pain.2010.07.028","article-title":"Fentanyl Pectin Nasal Spray 043 Study G. A multicenter, placebo-controlled, double-blind, multiple-crossover study of Fentanyl Pectin Nasal Spray (FPNS) in the treatment of breakthrough cancer pain","volume":"151","author":"Portenoy","year":"2010","journal-title":"Pain"},{"key":"10.1016\/j.clinthera.2014.12.010_bib23","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/pme.12184","volume":"14","author":"Webster","year":"2013","journal-title":"Pain Med"},{"key":"10.1016\/j.clinthera.2014.12.010_bib24","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1093\/annonc\/mdp541","article-title":"Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study","volume":"21","author":"Rauck","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clinthera.2014.12.010_bib25","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.1185\/03007990903368310","article-title":"Efficacy and long-term tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain","volume":"25","author":"Rauck","year":"2009","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2014.12.010_bib26","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1185\/03007995.2012.683111","article-title":"Efficacy and safety of fentanyl sublingual spray for the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study","volume":"28","author":"Rauck","year":"2012","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2014.12.010_bib27","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.jpainsymman.2013.07.012","article-title":"A Report on the Long-term Use of Fentanyl Pectin Nasal Spray in Patients With Recurrent Breakthrough Pain","volume":"47","author":"Taylor","year":"2014","journal-title":"J Pain Symptom Manage"},{"key":"10.1016\/j.clinthera.2014.12.010_bib28","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1185\/03007995.2010.545380","article-title":"Derrick R, Howell J. Long-term effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the treatment of breakthrough cancer pain","volume":"27","author":"Nalamachu","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.clinthera.2014.12.010_bib29","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1200\/JCO.2001.19.9.2542","article-title":"Strategies to manage the adverse effects of oral morphine: an evidence-based report","volume":"19","author":"Cherny","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clinthera.2014.12.010_bib30","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1038\/nrn1705","article-title":"Placebos and painkillers: is mind as real as matter?","volume":"6","author":"Colloca","year":"2005","journal-title":"Nat Rev Neurosci"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814008376?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291814008376?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,20]],"date-time":"2019-08-20T05:47:35Z","timestamp":1566280055000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291814008376"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["S0149291814008376"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2014.12.010","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2015,3]]}}}